Direct answer
What you need to know
Evidence strength: ModeratePrioritise adequate protein, fluids and nutrient-dense foods in portions you can tolerate. Pair nutrition with resistance exercise when it is safe for you; there is no single validated “GLP-1 diet.”
Key takeaways
- A smaller appetite can make protein and overall nutrition harder to meet.
- Lean mass in a DXA report is not the same as skeletal muscle.
- Smaller, slower meals may be easier when fullness or nausea is present.
- Persistent vomiting or inability to eat and drink needs medical advice, not a meal-plan workaround.
Important limitation: Most specific nutrition targets are extrapolated from broader weight-loss and muscle-preservation research; GLP-1-specific intervention trials remain limited.
Next action: Start with the tolerance-focused food guide, then discuss individual needs with your prescriber or a registered dietitian.
Primary sources: SURMOUNT-1 body-composition substudy
General educational information only. Kidney disease, pregnancy, diabetes treatment and eating-disorder history can change nutrition needs.
Your nutrition learning path
- Start here: what to eat and what to go easy onChoose foods around fullness, nausea and slower stomach emptying.
- See a sample meal patternA worked example—not a prescription—for distributing protein across smaller meals.
- Protect strength and muscleSeparate lean mass from skeletal muscle and compare training, protein and supplement evidence.
What the trial data actually shows
In the SURMOUNT-1 body-composition sub-study, 160 participants had their fat and lean mass measured by DXA scan before starting tirzepatide and again at 72 weeks. The results:
| Measure | Tirzepatide | Placebo |
|---|---|---|
| Total body weight | −21.3% | −5.3% |
| Fat mass | −33.9% | −8.2% |
| Lean mass | −10.9% | −2.6% |
Fat mass fell roughly three times faster than lean mass — the medication is doing what it is meant to do. But a real, measurable amount of lean tissue is lost alongside it, which is consistent with what happens during rapid weight loss by any method, not a GLP-1-specific problem. The practical question is how much of that lean-mass loss is avoidable.
The two things with actual evidence
Protein, specifically
Because appetite is reduced across the board, total food intake — including protein — typically falls unless you deliberately protect it. Research on preserving lean mass during GLP-1 treatment points to a target of roughly 1.2–1.6 grams of protein per kilogram of body weight per day, spread across meals rather than loaded into one. For a 200-lb (91 kg) person, that is roughly 109–145 grams a day — noticeably more than typical intake, and worth treating as a specific target rather than a vague “eat more protein” instruction. See a worked example in our sample meal plan.
Resistance exercise
Protein alone is a partial answer. The combination that shows up consistently in the lean-mass-preservation research is protein intake plus structured resistance training — not cardio alone. This is a conversation worth having with your prescriber or a physical therapist if you are new to resistance exercise, particularly if you have other health conditions.
What to actually eat, day to day
Beyond the protein target, most day-to-day food decisions on a GLP-1 are really about managing the gastrointestinal side effects — nausea, fullness, and constipation — described in our side-effects guide. See the specific do/avoid breakdown in what to eat, and what to go easy on.
What we are not claiming
There is no single validated "GLP-1 diet." Nutrition research in this specific population is still developing, and much of what is recommended is extrapolated from general rapid-weight-loss and sarcopenia-prevention research rather than GLP-1-specific trials. We have tried to be precise about which figures above come from a GLP-1 body-composition trial (the SURMOUNT-1 table) and which are general nutrition-science extrapolation (the protein target).
Sources
Each source below supports specific statements on this page. We cite the strongest available authority and verify against the current version before publishing.
- Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 studyDiabetes, Obesity and Metabolism (Look et al.)Supports: The DXA-measured fat mass vs. lean mass reduction figures at Week 72.
- Lean Mass and Musculoskeletal Preservation in GLP-1-Based Obesity TreatmentNutrients / MDPI (review)Supports: The protein-intake and resistance-training strategy for preserving lean mass.
- Clinical guidance on gastrointestinal effectsAmerican Gastroenterological AssociationSupports: Background on gastrointestinal tolerance considerations that shape food choice on GLP-1s.
- Diabetes, obesity and digestive-disease informationNational Institute of Diabetes and Digestive and Kidney Diseases (NIH)Supports: General nutrition background for obesity and diabetes treatment.
This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.